Summary of Key Points
The healthcare AI industry is at a critical turning point, moving from a focus on showcasing technology and competing with models to emphasizing the practical value and effectiveness of implementations. Senior executives, hospitals, and investors are becoming more pragmatic. They no longer solely concern themselves with model accuracy but ask questions such as: “How much money can it save? How many lives can it save?” “Where will the revenue come from? Can the results be replicated?” “Are there guarantees for clinical safety and compliance?” In the future, AI will become an essential infrastructure for healthcare companies. Those that fail to transform may lose their ability to make decisions quickly and their competitiveness.
Detailed Explanation
1. From “Showcasing Technology” to “Calculating Real Benefits”: Healthcare AI Enters a Phase of Value Verification
In the past, people evaluating healthcare AI would ask about model accuracy and the novelty of demonstrations. Now, the focus has shifted—investors and stakeholders are asking, “How much cost has this system helped hospitals save? Has it actually saved lives?” Senior executives are more interested in how AI has impacted business metrics (for example, whether it has shortened development cycles or improved hospital operational efficiency) and whether risks can be controlled (who is responsible for errors, and can the outcomes be traced?). The “value” of healthcare AI lies not just in generating profits but also in improving clinical quality, enhancing doctor experiences, and reducing risk costs (such as avoiding medical accidents). Only projects that can clearly demonstrate these benefits will continue to attract investment.
2. Common Pitfalls Faced by Companies Using AI
Many companies make the mistake of prioritizing technology over practical implementation. They purchase models and build platforms but fail to ensure that someone is accountable for the business outcomes. Healthcare processes are complex, and relying solely on technical teams is not enough to change doctor practices, comply with regulations, or modify IT systems. Some companies also choose scenarios that look impressive but are not practical. For example, generating medical records or answering medical questions may be visually appealing, but what really matters to businesses is AI that can shorten clinical trial cycles and reduce quality control risks. The key to success is to clearly define business problems (e.g., reducing the error rate in medical records), identify responsible parties for the outcomes, integrate AI into existing processes, and establish a data feedback mechanism (models need to be updated over time).
3. AI’s Impact on New Drug Development
AI’s role in new drug development goes beyond simply reducing costs and increasing efficiency; it also transforms the decision-making process. Traditional methods rely on expert experience and limited experiments, which can lead to detours. AI can analyze a wealth of data (literature, experimental results, clinical data) to help teams identify flawed assumptions more quickly and find promising research directions. In the future, a cycle of “model proposes hypotheses → experiments verify → data feeds back into the model → further optimization” may become standard, significantly accelerating the development process. For Chinese biotech companies, AI presents an opportunity to narrow the gap with global leaders (we have strong engineering capabilities and fast clinical implementation). However, without a deep understanding of disease mechanisms and global clinical experience, relying solely on algorithms is insufficient.
4. Challenges in Implementing AI in Hospitals
Many AI solutions work well in pilot hospitals but fail when applied in other settings due to differences in data formats (e.g., varying definitions of conditions), incompatible system interfaces, and doctor preferences, which significantly increase implementation costs. The challenge for hospitals is to scale these solutions. Effective approaches include focusing on the most feasible scenarios (e.g., improving the quality of medical records or accelerating patient turnover), clarifying responsibility for outcomes, and quantifying improvements (e.g., reducing the error rate in records). Additionally, it’s necessary to standardize data and transform processes to make AI more accessible to doctors.
5. Investors Becoming More Pragmatic
Investors are no longer just interested in fancy stories but in tangible results and scalability. They ask about revenue sources, customer repurchase behavior, and the ability to replicate solutions. They also distinguish between “project-based income” and “product-based income.” Projects that require custom modeling for each hospital, leading to increased costs as they scale, are less attractive. Companies that can develop standardized products suitable for multiple hospitals and address complex clinical needs are more appealing. Clinical evidence and compliance are becoming increasingly important factors in determining a company’s ability to generate significant revenue.
In Conclusion
The healthcare AI industry no longer lacks compelling stories; what’s needed are solutions that can effectively balance profitability, clinical safety, and compliance. In the next one to two years, those companies that can deliver tangible results will be the ones to thrive.